Tianjin Medical University Cancer Institute and Hospital: Colorectal Neoplasms trials
The registry lists 11 Colorectal Neoplasms studies with Tianjin Medical University Cancer Institute and Hospital as lead sponsor. 7 are open to participants now and 0 have results posted.
Phase 1 1Phase 2 8Phase 3 2No phase 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Hepatic Arterial Infusion of Liposomal Irinotecan Plus Oxaliplatin and Capecitabine as Adjuvant Therapy for Colorectal Cancer Liver MetastasesNot yet recruitingNCT07570914Phase 2
- A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colorectal CancerRecruitingNCT07506109Phase 2
- Liposomal Irinotecan (II) Fractionated Dosing Combined With 5-FU/LV (FOLFIRInali-3) and Bevacizumab in Second-line Treatment of Advanced Colorectal Cancer: A Single-arm, Phase II Clinical StudyRecruitingNCT07047560Phase 2
- Combination of LTC004 and Regorafenib to Treat Patients With Advanced/Metastatic CRCNot yet recruitingNCT06322563Phase 2
- Trifluridine/Tipiracil Combined With Oxaliplatin and Bevacizumab Versus XELOX Plus Bevacizumab in mCRCRecruitingNCT05077839Phase 2
- Study of Chemotherapy Combination With Autologous Cell Immunotherapy in the Recurrent and Metastatic Colorectal CancerRecruitingNCT03950154Phase 3
- Outcome of Resection for Colorectal CancerEnrolling by invitationNCT03837782Not applicable
- Fruquintinib Plus Checkpoint Inhibitor Combined or Sequential TAS-102 in Colorectal Cancer Patients Who Progressed on Second-line Standard Therapy: a Prospective, Multi-cohort, Single-centered, Phase Ib/II StudyActive, not recruitingNCT07491159Phase 1/2
- PD-1 Inhibitor Combined With Bevacizumab and FOLFIRI Regimen in the Second-line Treatment of Advanced Colorectal CancerStatus unknownNCT05035381Phase 2
- Efficacy and Safety of Sintilimab Combined With Regorafenib and Cetuximab / Sintilimab Combined With Regorafenib in Posterior Line Therapy of Advanced Colorectal Cancer (Regosinti)Status unknownNCT04745130Phase 2
- Monosialotetrahexosylganglioside Sodium Injection for Prevention Neurotoxicity of mFOLFOX 6 in mCRCStatus unknownNCT02024412Phase 3